CytImmune Sciences Inc.'s CYT-6091 Anti-Tumor Nanotherapeutic To Begin Testing In A Phase I Clinical Trial
Published: May 31, 2006
CytImmune Sciences Inc., an early clinical stage nano-medicine company focused on the development and targeted delivery of multifunctional anti- cancer therapeutics, announced today it has received notification from the FDA to commence a Phase I clinical trial to evaluate the safety, pharmacokinetics and clinical benefit of its lead drug candidate, CYT-6091, a TNF-bearing pegylated colloidal gold nanoparticle, in patients with advanced cancer. Up to 42 patients with advanced cancer whose disease has failed to respond to existing therapies or where no approved therapy is available may be enrolled in the study. The intravenously administered, dose- escalation study will be conducted at the National Cancer Institute (NCI) in Bethesda, Md.